-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immunome found that "super-responders" recovering from infection with the SARS-CoV-2 mutation were able to produce strong immune responses to a variety of viral targets, including prickly and non-tingling proteins.
Immunome is working to develop an antibody cocktail therapy, IM-BCP-001, that binds to SARS-CoV-2 virus surface prick proteins and non-hedgehog proteins, for the prevention and treatment of COVID-19.
In the process, Immunome identified antibodies that bind to non-overlapping regions of the prickly protein (non-overlapping regions, including regions containing key mutations) and showed in active tests that it was able to mediate the prosthetic virus that was specific to the South African mutant strain B.1.351.
recent literature suggests that the South African mutant strain weakens the efficacy of vaccines and some existing antibody therapies.
, chief executive of Immunome, said: "Our findings demonstrate Immunome's ability to quickly screen extremely mutant strains of the SARS-CoV-2 virus.
we have found antibodies that bind to the conservative bits of SARS-CoV-1 and SARS-CoV-2 virus hedgehog proteins, and believe that our strategy can help fight some mutant strains.
2020, Immunome received $13.3 million from the U.S. government to support the development of its COVID program.